A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective
Kotowa, Wioletta, Gatzemeier, Ulrich, Pirk, Olaf, Gabriel, Anja, Heigener, DavidVolume:
10
Language:
english
Journal:
Journal of Medical Economics
DOI:
10.3111/13696990701438637
Date:
January, 2007
File:
PDF, 734 KB
english, 2007